Nuclear accumulation of β-catenin protein in Wilms' tumours

Journal of Pathology

Volumn 199, Issue 1, 2003, Pages 68-76

  Koesters, Robert ^a   Niggli, Felix ^b   von Knebel Doeberitz, Magnus ^a   Stallmach, Thomas ^c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b University Children's Hospital   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

catenin; Immunohistochemistry; Mutations; Wilms' tumours; WT1

Indexed keywords

BETA CATENIN; CYTOPLASM PROTEIN; MEMBRANE PROTEIN; NUCLEAR PROTEIN; WNT PROTEIN;

ANTIGEN SPECIFICITY; ARTICLE; BLAST CELL; CANCER STAGING; CARCINOGENESIS; CELL DIFFERENTIATION; CELL NUCLEUS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MESENCHYME CELL; NEPHROBLASTOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ADOLESCENT; BETA CATENIN; CELL MEMBRANE; CELL NUCLEUS; CHILD; CHILD, PRESCHOOL; CYTOPLASM; CYTOSKELETAL PROTEINS; FEMALE; GENES, WILMS TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KIDNEY; KIDNEY NEOPLASMS; MALE; MUTATION; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TRANS-ACTIVATORS; WILMS TUMOR;

EID: 0037221160     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1248     Document Type: Article

References (58)

1. Breslow N, Beckwith JB, Ciol M, Sharples K. Age distribution of Wilms' tumor: report from the National Wilms' Tumor Study. Cancer Res 1988; 48: 1653-1657.
2. Breslow NE, Langholz B. Childhood cancer incidence: geographical and temporal variations. Int J Cancer 1983; 32: 703-716.
3. Matsunaga E. Genetics of Wilms' tumor. Hum Genet 1981; 57: 231-246.
4. Exelby PR. Wilms' tumor 1991. Clinical evaluation and treatment. Urol Clin North Am 1991; 18: 589-597.
5. Van HV, Boyd PA, Seawright A, et al. Molecular analysis of chromosome 11 deletions in aniridia-Wilms' tumor syndrome. Proc Natl Acad Sci U S A 1985; 82: 8592-8596.
6. Mannens M, Slater RM, Heyting C, et al. Molecular nature of genetic changes resulting in loss of heterozygosity of chromosome 11 in Wilms' tumours. Hum Genet 1988; 81: 41-48.
7. Maw MA, Grundy PE, Millow LJ, et al. A third Wilms' tumor locus on chromosome 16q. Cancer Res 1992; 52: 3094-3098.
8. Steenman M, Redeker B, de Meulemeester M, et al. Comparative genomic hybridization analysis of Wilms' tumors. Cytogenet Cell Genet 1997; 77: 296-303.
9. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 1994; 54: 2331-2333.
10. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-520.
11. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms' tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343: 774-778.
12. Hosono S, Gross I, English MA, Hajra KM, Fearon ER, Licht JD. E-cadherin is a WT1 target gene. J Biol Chem 2000; 275: 10 943-10 953.
13. Nichols KE, Re GG, Yan YX, Garvin AJ, Haber DA. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. Cancer Res 1995; 55: 4540-4543.
14. Werner H, Re GG, Drummond IA, et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms' tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms' tumor gene product. Proc Natl Acad Sci U S A 1993; 90: 5828-5832.
15. Wang ZY, Madden SL, Deuel TF, Rauscher FJ III. The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem 1992; 267: 21 999-22 002.
16. Gashler AL, Swaminathan S, Sukhatme VP. A novel repression module, an extensive activation domain, and a bipartite nuclear localization signal defined in the immediate-early transcription factor Egr-1. Mol Cell Biol 1993; 13: 4556-4571.
17. Cook DM, Hinkes MT, Bernfield M, Rauscher FJ III. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene 1996; 13: 1789-1799.
18. Ryan G, Steele-Perkins V, Morris JF, Rauscher FJ III, Dressler GR. Repression of Pax-2 by WT1 during normal kidney development. Development 1995; 121: 867-875.
19. Kim J, Prawitt D, Bardeesy N, et al. The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation. Mol Cell Biol 1999; 19: 2289-2299.
20. Lee SB, Huang K, Palmer R, et al. The Wilms' tumor suppressor WT1 encodes' a transcriptional activator of amphiregulin. Cell 1999; 98: 663-673.
21. Varanasi R, Bardeesy N, Ghahremani M, et al. Fine structure analysis of the WT1 gene in sporadic Wilms' tumors. Proc Natl Acad Sci U S A 1994; 91: 3554-3558.
22. Koesters R, Adams V, Hassam S, et al. Mutational analysis of the tumor suppressor gene WT1: detection of a novel homozygous point mutation in sporadic unilateral Wilms' tumor. Int J Oncol 1995; 7: 1103-1107.
23. Maiti S, Alam R, Amos CI, Huff V. Frequent association of β-catenin and WT1 mutations in Wilms' tumors. Cancer Res 2000; 60: 6288-6292.
24. Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nature Genet 1994; 7: 91-97.
25. Koesters R, Ridder R, Kopp-Schneider A, et al. Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 1999; 59: 3880-3882.
26. Gumbiner BM. Signal transduction of β-catenin. Curr Opin Cell Biol 1995; 7: 634-640.
27. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-1851.
28. Itoh K, Krupnik VE, Sokol SY. Axis determination in Xenopus involves biochemical interactions of axin, glycogen synthase kinase 3 and β-catenin. Curr Biol 1998; 8: 591-594.
29. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of β-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996; 10: 1443-1454.
30. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-3804.
31. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway [see comments]. Science 1998; 281: 1509-1512.
32. Tetsu O, McCormick F. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-426.
33. Robbins PF, El Gamil M, Li YF, et al. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996; 183: 1185-1192.
34. Kitaeva MN, Grogan L, Williams JP, et al. Mutations in β-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. Cancer Res 1997; 57: 4478-4481.
35. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58: 1130-1134.
36. Murata M, Iwao K, Miyoshi Y, et al. Molecular and biological analysis of carcinoma of the small intestine: β-catenin gene mutation by interstitial deletion involving exon 3 and replication error phenotype. Am J Gastroenterol 2000; 95: 1576-1580.
37. Zurawel RH, Chiappa SA, Allen C, Raffel C. Sporadic medulloblastomas contain oncogenic β-catenin mutations. Cancer Res 1998; 58: 896-899.
38. De La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998; 95: 8847-8851.
39. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the β-catenin gene. Cancer Res 1999; 59: 269-273.
40. Miyoshi Y, Iwao K, Nagasawa Y, et al. Activation of the β-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998; 58: 2524-2527.
41. Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 235-237.
42. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170.
43. Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nature Genet 2000; 24: 245-250.
44. Iwao K, Nakamori S, Kameyama M, et al. Activation of the β-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 1998; 58: 1021-1026.
45. Inomata M, Ochiai A, Akimoto S, Kitano S, Hirohashi S. Alteration of β-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Res 1996; 56: 2213-2217.
46. Palacios J, Gamallo C. Mutations in the β-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998; 58: 1344-1347.
47. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. β-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998; 58: 3526-3528.
48. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of β-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999; 154: 325-329.
49. Voeller HJ, Truica CI, Gelmann EP. β-catenin mutations in human prostate cancer. Cancer Res 1998; 58: 2520-2523.
50. Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA. Activation of β-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000; 19: 498-504.
51. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999; 155: 703-710.
52. Eberhart CG, Tihan T, Burger PC. Nuclear localization, mutation of β-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000; 59: 333-337.
53. Brabletz T, Herrmann K, Jung A, Faller G, Kirchner T. Expression of nuclear beta-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. Am J Pathol 2000; 156: 865-870.
54. Jung A, Schrauder M, Oswald U, et al. The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol 2001; 159: 1613-1617.
55. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF. β-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 1997; 94: 10 330-10 334.
56. Rubinfeld B, Robbins P, El Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of β-catenin by genetic defects in melanoma cell lines. Science 1997; 275: 1790-1792.
57. Mannens M, Devilee P, Bliek J, et al. Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11. Cancer Res 1990; 50: 3279-3283.
58. Hoban PR, Cowen RL, Mitchell EL, et al. Physical localisation of the breakpoints of a constitutional translocation t(5;6)(q21;q21) in a child with bilateral Wilms' tumour. J Med Genet 1997; 34: 343-345.